Glaxosmithkline | الأصول



Assets تغيير تاريخ
AbbVie USD 135.16B 8.26B 2024-12
Amgen USD 89.37B 2.47B 2025-03
AstraZeneca USD 106.25B 2.22B 2025-03
Aurora Cannabis CAD 866.52M 57.75M 2024-12
Bausch Health Companies USD 26.42B 102M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Canopy Growth CAD 1.16B 68.13M 2024-12
Corcept Therapeutics USD 846.46M 5.9M 2025-03
Drreddys Laboratories INR 481.06B 15.1B 2024-12
Eli Lilly USD 89.39B 10.67B 2025-03
GlaxoSmithKline GBP 60.71B 1.24B 2025-03
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Indivior 1.38B 56M 2025-03
J&J USD 193.67B 13.57B 2025-03
Merck USD 115.12B 1.98B 2025-03
Novartis USD 102.25B 1.28B 2024-12
Pacira USD 1.59B 33.15M 2025-03
Perrigo USD 9.76B 112.1M 2025-03
Pfizer USD 208.03B 5.37B 2025-03
Prestige Brands USD 3.4B 72.72M 2025-03
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 131.89B 906M 2025-03
Supernus Pharmaceuticals USD 1.37B 25.37M 2024-12
Takeda JPY 14.25T 858.5B 2025-03
Teva Pharmaceutical Industries USD 38.42B 911M 2025-03
Zoetis USD 14.1B 139M 2025-03



Glaxosmithkline الأصول - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - May 2025.